secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001437749-24-005624
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar names Prof. Rodney Hicks lead investigator for MNPR-101-Zr Phase 1 trial
--------------------------------------------------------------------------------

- Professor Rodney Hicks to lead MNPR-101-Zr Phase 1 dosimetry trial in advanced cancer patients.
- Trial will use Siemens Biograph Vision Quadra total-body PET/CT, one of the most sensitive clinical scanners.
- MNPR-101-Zr targets cancers with high unmet need, including pancreatic and triple-negative breast cancer.
- Enrollment expected to begin shortly at Melbourne Theranostic Innovation Centre (MTIC).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924005624/0001437749-24-005624-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924005624/mnpr20240226_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-005624

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer